Christopher Fortner, MD, PhD

VX20-121-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation
Read more

Participation in the Cystic Fibrosis Patient Registry
Read more